bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 4,900 shares of the firm’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $129.94, for a total value of $636,706.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
bluebird bio, Inc. (NASDAQ:BLUE) opened at 130.20 on Friday. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $143.50. The stock has a 50 day moving average price of $125.54 and a 200 day moving average price of $101.98. The company’s market capitalization is $5.94 billion.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.66) by ($0.07). The firm had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The business’s revenue was up 977.4% on a year-over-year basis. During the same period last year, the company posted ($1.59) earnings per share. Equities research analysts forecast that bluebird bio, Inc. will post ($6.79) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Jeffrey T. Walsh Sells 4,900 Shares of bluebird bio, Inc. (BLUE) Stock” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/10/13/jeffrey-t-walsh-sells-4900-shares-of-bluebird-bio-inc-blue-stock.html.
Several large investors have recently modified their holdings of BLUE. QS Investors LLC raised its stake in bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares in the last quarter. Bank of Montreal Can raised its stake in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares in the last quarter. Turner Investments LLC bought a new position in bluebird bio in the second quarter worth about $184,000. SG Americas Securities LLC raised its stake in bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after buying an additional 295 shares in the last quarter. Finally, Fairfield Bush & CO. bought a new position in bluebird bio in the second quarter worth about $210,000.
Several brokerages recently issued reports on BLUE. Jefferies Group LLC reaffirmed a “hold” rating and set a $126.00 target price on shares of bluebird bio in a research report on Wednesday. Maxim Group reaffirmed a “buy” rating and set a $170.00 target price (up from $100.00) on shares of bluebird bio in a research report on Monday. Leerink Swann reaffirmed an “outperform” rating and set a $145.00 target price (up from $120.00) on shares of bluebird bio in a research report on Friday, October 6th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research report on Friday, October 6th. Finally, Morgan Stanley lowered bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 target price for the company. in a research report on Monday, October 2nd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the stock. bluebird bio presently has an average rating of “Hold” and an average price target of $118.81.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.